Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

CARIS LIFE SCIENCES, INC.

Filed by CARIS LIFE SCIENCES, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-10-29 06:26:14 UTC.

Source-reported fields

Filing overview

Type
Registration - Amendment
Posted
Oct 20, 2026
Income
Not reported
Expenses
Not reported
Filing UUID
290ae483-95f8-4e4e-bc4e-d47118fe1f7e
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;

Literal federal measure citations: S 2355

HCR · Health Issues

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;

Literal federal measure citations: S 2355

MED · Medical/Disease Research/Clinical Labs

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;

Literal federal measure citations: S 2355

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.